Applied DNA Sciences, Inc.

APDN

US03815U4094

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-09 pm EDT			5-day change	1st Jan Change
3.74 ^USD	+0.13%		-8.56%	-69.68%

May. 07	Banned Chinese cotton found in 19% of US retailers' merchandise, study shows	RE
Apr. 25	Applied DNA Sciences, Inc. Receives Contract by HDT Bio for Rapid Vaccine Development Program	CI

Applied DNA Sciences, Inc. Appoints Joseph D. Ceccoli to the Audit Committee

November 14, 2019 at 06:04 am EST

On November 12, 2019, Applied DNA Sciences, Inc. appointed Joseph D. Ceccoli, who is currently serving as an independent director on the board of directors of the Company, to the audit committee.

Latest news about Applied DNA Sciences, Inc.

Banned Chinese cotton found in 19% of US retailers' merchandise, study shows	May. 07	RE
Applied DNA Sciences, Inc. Receives Contract by HDT Bio for Rapid Vaccine Development Program	Apr. 25	CI
Certain Warrants of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024.	Apr. 02	CI
Certain Options of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024.	Apr. 02	CI
Certain Common Stock of Applied DNA Sciences, Inc. are subject to a Lock-Up Agreement Ending on 3-APR-2024.	Apr. 02	CI
Applied DNA Sciences, Inc. to Showcase Linea DNA and Linea IVT Platforms At 24Th Annual World Vaccine Congress	Mar. 14	CI
Applied DNA Sciences Files Prospectus for Potential Secondary Stock Offerings	Mar. 12	MT
Transcript : Applied DNA Sciences, Inc., Q1 2024 Earnings Call, Feb 08, 2024	Feb. 08
Earnings Flash (APDN) APPLIED DNA SCIENCES Reports Q1 Revenue $891,164	Feb. 08	MT
Applied DNA Sciences, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Feb. 08	CI
Applied DNA Sciences, Inc. Announces Joint Development Agreement to Integrate Linea IVT Platform into CDMO Kudo Biotechnology?s mRNA Manufacturing Workflow	Dec. 14	CI
HC Wainwright Cuts Price Target on Applied DNA Sciences to $2 From $4, Keeps Buy Rating	Dec. 08	MT
Transcript : Applied DNA Sciences, Inc., Q4 2023 Earnings Call, Dec 07, 2023	Dec. 07
Earnings Flash (APDN) APPLIED DNA SCIENCES Posts Q4 Revenue $779,736, vs. Street Est of $1.7M	Dec. 07	MT
Applied DNA Sciences, Inc. Reports Earnings Results for the Fourth Quarter Ended September 30, 2023	Dec. 07	CI
Applied DNA Sciences, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Dec. 07	CI
Applied DNA Sciences, Inc. Announces Receipt of Linea(TM) DNA Follow-On Order for Cancer Diagnostic Application	Nov. 28	CI
Applied DNA Sciences, Inc. Extends Application of Linea(Tm) Ivt Platform to Sna (Self-Amplifying Mrna)	Nov. 16	CI
Applied DNA Sciences, Inc. Advances Commercialization of Linea(TM) IVT Platform	23-09-06	CI
Applied DNA Sciences, Inc. Announces Appointment of Beverly Wolgast as Executive Director of Quality and cGMP Programs	23-09-06	CI
Applied DNA Sciences, Inc. Announces Availability and First Customer Shipment of New Linea(TM) IVT Evaluation Kit	23-08-29	CI
Applied DNA Sciences Files Patent Applications for mRNA Production by Reducing Double-Stranded RNA	23-08-23	MT
Applied DNA Sciences, Inc. Files Provisional Patent Applications for Methods of Double-Stranded RNA Mitigation in Next-Generation mRNA Production	23-08-23	CI
HC Wainwright Adjusts Price Target on Applied DNA Sciences to $4 From $5, Keeps Buy Rating	23-08-14	MT
Transcript : Applied DNA Sciences, Inc., Q3 2023 Earnings Call, Aug 10, 2023	23-08-10

Chart Applied DNA Sciences, Inc.

Duration

Period

More charts

Applied DNA Sciences, Inc. is a biotechnology company that develops, and markets deoxyribonucleic acid (DNA) based technology solutions. The Company is utilizing its LinearDNA large-scale polymerase chain reaction (PCR) based manufacturing platform. The Companyâs proprietary platform produces large quantities of DNA for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets and for supply chain security, anti-counterfeiting and anti-theft technology purposes. It also develops PCR-based molecular in vitro diagnostics for covid-19. In addition, under its wholly owned subsidiary, Applied DNA Clinical Labs, LLC, the Company is offering a high-throughput turnkey solution for population-scale Covid-19 testing marketed as safeCircle. safeCircle utilizes the Companyâs Covid-19 Diagnostic Tests and is designed to look for infection within defined populations or communities utilizing high throughput testing methodologies.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-08-07 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Applied DNA Sciences, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

3.74 USD

Average target price

45 USD

Spread / Average Target

+1,103.21%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
APPLIED DNA SCIENCES, INC.	-69.68%	3.23M
BIOMÉRIEUX	+0.10%	12.64B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-1.64%	8.37B
DIASORIN S.P.A.	+0.49%	5.37B
LANTHEUS HOLDINGS, INC.	+22.42%	5.26B
AUTOBIO DIAGNOSTICS CO., LTD.	-0.09%	4.58B
10X GENOMICS, INC.	-52.84%	3.16B
ANDON HEALTH CO., LTD.	+20.02%	2.89B
VITROLIFE AB	-8.27%	2.22B
GUANGZHOU WONDFO BIOTECH CO.,LTD	-2.45%	1.91B

Diagnostic & Testing Substances